Coloplast

Impact4 Efficiency Targets And Kerecis Margins Will Shape Long Term Earnings Trajectory

AnalystLowTarget

Not Invested

Community Contributor

Published

11 Dec 25

n/a

AnalystLowTarget's Fair Value

n/a

-31.6%

-3.0%

-31.6%

-3.0%

You can edit this narrative until Dec 12 4:05 PM. Then, changes will post as Updates.

Author's Valuation

DKK 5355.4% overvalued

AnalystLowTarget Fair Value

Narrative

Updates0

AnalystLowTarget Fair Value

DKK 535

5.4% overvalued

Future estimation in

% p.a.

Decrease

Increase

Current revenue growth rate

6.78%

Medical Equipment revenue growth rate

8.17%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

Decrease

Increase

Current discount rate

6.08%

Calculation

DKK 6.82b

Earnings '28

21.18x

PE Ratio '28

DKK 144.41b

Market Cap '28

DKK 144.41b

Market Cap '28

225.97m

No. shares '28

DKK 639.09

Share Price '28

DKK 639.09 Share Price '28

Discounted to 2025 @ 6.11% p.a.

DKK 535.00

Fair Value '25